The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARα gene rearrangements

Haematologica

Volumn 84, Issue 5, 1999, Pages 405-412

  Orfao, Alberto ^a,b   Chillón, María Carmen ^a   Bortoluci, Aglaê Ma ^a   López Berges, María Consuelo ^a   García Sanz, Ramón ^a   Gonzalez, Marcos ^a   Tabernero, María Dolores ^b   García Marcos, María Antonia ^a   Rasillo, Ana Isabel ^b   Hernández Rivas, Jesús ^a   San Miguel, Jesús F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Acute myeloblastic leukemia; t(15; 17)

Indexed keywords

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CHILD; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC SCREENING; HUMAN; IMMUNOPHENOTYPING; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PROGNOSIS; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD13; ANTIGENS, CD15; ANTIGENS, CD34; CHILD; FEMALE; FLOW CYTOMETRY; GENE REARRANGEMENT; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, RETINOIC ACID;

EID: 0032849301     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Awisati G, Lo Coco F, Diverio D, et al. AIDA (all-trans-retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88:1390-8.
2. Fenaux P, Chastang CI, Sanz M, et al. Effect of ATRA in newly diagnosed acute promyelocytic leukemia (APL): validation of short term effect in a large multicenter trial (APL 93 Trial) and assessment of long term benefit (APL 91 Trial) [abstract]. Blood 1996; 88: (Suppl 1): 209a.
3. Fenaux P, Le Deley MC, Castaigne S, et al. Effect of all-trans-retinoic acid in newly diagnosed acute promyelocytic leukemia: Results of a multicenter randomized trial. Blood 1993; 82:3241-9.
4. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia: results of the New York Study. Ann Intern Med 1994; 120:278-86.
5. Kanamaru A, Takemoto Y, Tanimoto M, et al. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85:1202-6.
6. Mandelli F, Diverio D, Awisati G, et al. Molecular remission in PML-RARα-positive acute promyelocytic leukemia by combined all-trans-retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90:1014-21.
7. Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia [letter]. Lancet 1977; 1:549-50.
8. Fagioli M, Alcalay M, Pandolfi PP, et al. Alternative splicing of PML transcripts predicts coexpression of several carboxy-terminally different protein isoforms. Oncogene 1992; 7:1083-91.
9. Miller WH Jr, Kakizuka A, Frankel SR, et al. Reverse transcription polymerase chain reaction for the rearranged retinoic receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89: 2694-8.
10. Douer D, Preston-Martin S, Chang E, et al. High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia. Blood 1996; 87:308-13.
11. Sanz MA, Martin G, Diaz-Mediavilla J. All-trans-retinoic acid in acute promyelocytic leukemia [letter]. N Engl J Med 1997; 338:393.
12. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021-8.
13. Betz SA, Foucar K, Head DR, et al. False-positive flow cytometric platelet glycoprotein IIb/IIIa expression in myeloid leukemias secondary to platelet adherence to blasts. Blood 1992; 79:2399-403.
14. Lo Coco F, Awisati G, Diverio D, et al. Rearrangements of the RARa gene in acute promyelocytic leukemia: Correlations with morphology and immunophenotype. Br J Haematol 1991; 78:494-9.
15. Paietta E, Andersen J, Gallagher R, et al. The immunophenotype of acute promyelocytic leukemia (APL): An ECOC study. Leukemia 1994; 8:1108-12.
16. San Miguel JF, Gonzaαlez M, Cañizo MC, et al. Surface marker analysis in acute myeloid leukemia and correlation with FAB classification. Br J Haematol 1986; 64: 547-60.
17. Bene MC, Castoldi G, Knapp W, et al. and the European Group for the Immunological Characterization of Leukaemias. Proposals for the immunological classification of acute leukemias. Leukemia. 1995; 9:1783-6.
18. Rothe G, Schmitz G for the Working Group on Flow Cytometry and Image Analysis and members of the editorial committee: Adorf D, Barlage S, Gramatzki M et al. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 1996; 10:877-95.
19. Ruiz-Arguelles A, Duque RE, Orfao A. Report on the first Latin-American consensus conference for flow cytometric immunophenotyping of leukemia. Cytometry 1998; 34:39-42.
20. Daniel MT, Koken M, Romagne O, et al. PML protein expression in hematopoietic and acute promyelocytic leukemia cells. Blood 1993; 82:1858-67.
21. Dyck JA, Warrell RP, Evans RM, et al. Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RARα protein. Blood 1996; 86:862-7.
22. Falini B, Flenghi L, Fagioli M, et al. Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). Blood 1997; 90:4046-53.
23. Koken MHM, Puvion-Dutilleul F, Guillemin MC, et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994; 13: 1073-83.
24. Borowitz MJ, Bray R, Gascoyne R, et al. U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry 1997; 30:236-44.
25. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Int Med 1985; 103:620-5.
26. Macedo A, Orfao A, Vidriales MB, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol 1995; 70:189-94.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-9.
28. Biondi A, Rambaldi A, Pandolfi PP, et al. Molecular monitoring of the myl-retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992; 80:492-7.
29. Borrow J, Goddard AD, Gibbons B, et al. Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARα and RARα-PML fusion transcripts. Br J Haematol 1992; 82:529-40.
30. Diverio D, Lo Coco F, D'Adamo F, et al. Identification of DNA rearrangements at the retinoic acid receptor-α (RAR-α) locus in all patients with acute promyelocytic leukemia (APL) and mapping of APL breakpoints within the RAR-α second intron. Blood 1992; 79:3331-6.
31. Davis BH, Foucar K, Szczarkowski W, et al. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: medical indications. Cytometry 1997; 30: 249-63.
32. San Miguel JF, Martínez A, Macedo A, et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90:2465-70.
33. Adriaansen HJ, Jacobs BC, Kappers-Klunne MC, et al. Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. Leukemia 1993; 7:472-81.
34. Haferlach T, Gassmann W, Loffler H, et al for the AML Cooperative Group Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. Ann Hematol 1993; 66:165-70.
35. Larson RA, Williams SF, Le Beau MM, et al. Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 1986; 68:1242-9.
36. Paietta E, Wrenik PH, Andersen J, et al. Acute myeloid leukemia M4 with inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression [letter]. Blood 1993; 82:2595.
37. Hurwitz CA, Raimondi SC, Head D, et al. Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood 1992; 80: 3182-8.
38. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8:21)(q22:q22) chromosomal abnormality: Frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood 1992; 80:470-7.
39. Claxton DF, Reading CL, Nagarajan L, et al. Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 1992; 80: 582-6.
40. Rovelli A, Biondi A, Rajnoldi AC, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol 1992; 10:1413-8.
41. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma. Blood 1986; 68:1-31.
42. Traveek ST. Immunophenotypic analysis of acute leukemia. Am J Clin Pathol 1993; 99:504-12.